In the progression from DCIS to IBC, T cells progressively encounter increasing stimulation from the presence of the HER2 antigen on tumor cells, so as disease progresses, CD4+ T cells are more likely to undergo activation-induced cell death from continued stimulation and activation with MHC/peptide complexes. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.